162 Participants Needed

Olaparib + Chemotherapy for Advanced Ovarian Cancer

Recruiting at 49 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Do I need to stop taking my current medications to join the trial?

The trial protocol does not specify if you need to stop taking your current medications, but you cannot be on any systemic anticancer chemotherapy or radiotherapy within two weeks before starting the study treatment.

What data supports the effectiveness of the drug combination of Olaparib, Carboplatin, and Paclitaxel for advanced ovarian cancer?

Research shows that the combination of Olaparib and Carboplatin is tolerable and provides clinical benefits in certain patients with heavily pretreated ovarian cancer, even if they are resistant to platinum-based treatments. Additionally, Olaparib has shown effectiveness as a maintenance therapy in relapsed ovarian cancer, helping to delay disease progression.12345

Is the combination of Olaparib and chemotherapy safe for treating advanced ovarian cancer?

Research shows that Olaparib, when used alone or with chemotherapy, is generally safe for treating ovarian cancer. Common side effects include mild anemia (low red blood cell count), fatigue, vomiting, diarrhea, and nausea, which are usually manageable.34678

What makes the drug combination of Olaparib, Carboplatin, and Paclitaxel unique for treating advanced ovarian cancer?

This drug combination is unique because it combines Olaparib, a PARP inhibitor that targets cancer cells with specific genetic mutations, with Carboplatin and Paclitaxel, which are chemotherapy drugs that work by damaging the DNA of cancer cells. This combination aims to enhance the effectiveness of treatment by using different mechanisms to control the disease.135910

What is the purpose of this trial?

To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.

Research Team

AO

Amit Oza, MD

Principal Investigator

Princess Margaret Hospital, Canada

JR

Jane Robertson, BSc, MBCHB, MD

Principal Investigator

AstraZeneca

Eligibility Criteria

This trial is for patients with advanced ovarian cancer who have had no more than three prior platinum treatments and were progression-free for at least six months after the last one. They must have at least one measurable lesion and be diagnosed with serous ovarian cancer. Those with recent chemotherapy, radiotherapy, or hypersensitivity to related medications cannot participate.

Inclusion Criteria

I have been diagnosed with serous ovarian cancer.
You have a visible and measurable lesion that can be monitored over time.
I've had up to 3 platinum treatments and was stable for 6+ months after.

Exclusion Criteria

I haven't had chemotherapy or radiotherapy (except for pain relief) in the last two weeks.
I am allergic to the medications given before paclitaxel/carboplatin treatment.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive olaparib in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone

18 weeks
Radiologic scans at weeks 9 and 18

Follow-up

Participants are monitored for progression-free survival and overall survival

20 months
Every 12 weeks

Long-term follow-up

Participants are contacted every 12 weeks to assess survival status

50 months

Treatment Details

Interventions

  • Carboplatin
  • Olaparib
  • Paclitaxel
Trial Overview The study compares the effectiveness of Olaparib combined with Carboplatin and Paclitaxel versus just Carboplatin and Paclitaxel in treating advanced ovarian cancer. The goal is to see if adding Olaparib improves patient outcomes.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: 1Experimental Treatment3 Interventions
Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator. Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions.
Group II: 2Active Control2 Interventions
paclitaxel iv and carboplatin iv

Carboplatin is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Paraplatin for:
  • Ovarian cancer
  • Testicular cancer
  • Lung cancer
  • Head and neck cancer
  • Brain cancer
🇪🇺
Approved in European Union as Carboplatin for:
  • Ovarian cancer
  • Small cell lung cancer
🇨🇦
Approved in Canada as Carboplatin for:
  • Ovarian cancer
  • Small cell lung cancer
  • Testicular cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

AstraZeneca

Lead Sponsor

Trials
4,491
Recruited
290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Findings from Research

In a study of 120 ovarian cancer patients, the combination of olaparib with paclitaxel and carboplatin significantly improved the objective remission rate and disease control rate compared to the standard treatment with paclitaxel and carboplatin alone.
The addition of olaparib also resulted in lower levels of tumor markers and a reduced rate of tumor metastasis after one year, all without increasing the incidence of adverse effects.
Olaparib and paclitaxel in combination with carboplatin in treatment of ovarian cancer: influence on disease control.Zhang, H., Zhang, Y.[2022]
The combination of olaparib and carboplatin is tolerable and shows clinical benefit in patients with BRCA wild-type high-grade serous ovarian carcinoma, with a clinical benefit rate of 64% in heavily pretreated patients.
The maximum tolerated dose was established at olaparib 400 mg twice daily with carboplatin AUC4, although significant side effects like neutropenia and thrombocytopenia were observed, indicating the need for careful monitoring during treatment.
Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.Lampert, EJ., Hays, JL., Kohn, EC., et al.[2023]
The OPINION study is evaluating the safety and efficacy of olaparib as a maintenance therapy for women with high-grade serous or endometrioid platinum-sensitive relapsed ovarian cancer who do not have BRCA mutations, involving patients who have undergone at least two prior lines of platinum-based chemotherapy.
The primary goal of the study is to assess progression-free survival, which will help determine how effective olaparib is in delaying cancer progression in this specific patient population.
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.Poveda, AM., Davidson, R., Blakeley, C., et al.[2020]

References

Olaparib and paclitaxel in combination with carboplatin in treatment of ovarian cancer: influence on disease control. [2022]
Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. [2023]
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design. [2020]
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. [2022]
Safety evaluation of olaparib for treating ovarian cancer. [2015]
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. [2022]
Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials. [2020]
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. [2016]
Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer. [2022]
Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. [2016]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security